Among growth hormone axis peptides, few combinations have attracted as much sustained research interest as the tesamorelin/ipamorelin pairing. One is an FDA-approved GHRH analogue with a documented clinical track record. The other is a highly selective ghrelin mimetic with a reputation for a remarkably clean side-effect profile. Together, they target the same biological endpoint—amplified, pulsatile GH release—through complementary and synergistic mechanisms. This article breaks down the science, the research landscape, and what serious investigators are discussing in 2026.
What Is the Tesamorelin/Ipamorelin Combination?
Tesamorelin (trade name Egrifta) is a synthetic analogue of growth hormone-releasing hormone (GHRH). It is structurally identical to endogenous GHRH(1–44) with a trans-3-hexenoic acid group at the N-terminus that stabilizes the molecule against dipeptidyl peptidase IV (DPP-IV) degradation, extending its half-life to approximately 26 minutes. The FDA approved tesamorelin in 2010 for reduction of visceral adipose tissue (VAT) in HIV-infected patients with antiretroviral-associated lipodystrophy. In research contexts, investigators are exploring its broader effects on body composition, metabolic markers, and cognitive function.
Ipamorelin is a pentapeptide growth hormone secretagogue (GHS) and selective ghrelin receptor agonist (GHSR-1a). Unlike older GHRPs such as GHRP-2 or GHRP-6, ipamorelin does not meaningfully stimulate cortisol, prolactin, or ACTH at therapeutic doses, making it one of the most studied “clean” GHRPs available. Its half-life is approximately 2 hours in preclinical models.
The rationale for combining them is well-grounded in pituitary physiology. GHRH (tesamorelin) stimulates somatotroph cells to synthesize and release GH, while ghrelin/GHSR agonists (ipamorelin) amplify the GH pulse through a distinct intracellular cascade involving protein kinase C. Co-administration of a GHRH analogue with a GHRP produces GH pulses that are significantly larger than either agent alone—a phenomenon documented in both rodent models and human clinical studies.
Research Overview
The clinical evidence for tesamorelin is among the strongest of any research peptide. The phase III LIPO studies demonstrated that daily subcutaneous tesamorelin (2 mg/day) reduced VAT by approximately 15–18% over 26 weeks versus placebo in HIV-positive patients, with corresponding improvements in triglycerides and trunk fat ratio (Falutz et al., NEJM 2010). A subsequent 52-week extension confirmed sustained visceral fat reduction with continued use and partial reversal upon discontinuation (Falutz et al., Lancet HIV 2013).
Beyond body composition, a randomized controlled trial in older adults with mild cognitive impairment found that tesamorelin improved executive function and verbal memory compared to placebo over 20 weeks, with results correlating with IGF-1 elevation (Baker et al., Nature Aging 2021). This cognitive angle has generated significant interest in longevity research circles.
For ipamorelin, key preclinical work has demonstrated significant GH release, lean mass gains, and bone mineral density preservation in rat models without the cortisol and prolactin spikes seen with older GHRPs (Raun et al., Eur J Endocrinol 1998). Human data from combination GHRH+GHRP studies consistently show that the synergistic GH response exceeds either peptide alone by a factor of 2–3x (Bowers et al., J Clin Endocrinol Metab 1995).
Community Discussion
The r/Peptides subreddit hosts one of the most active ongoing discussions of tesamorelin/ipamorelin stacking protocols. Researchers there frequently compare this combination favorably to CJC-1295/ipamorelin stacks, noting that tesamorelin’s more physiological GHRH mimicry may produce a cleaner pulsatile pattern. Discussions also cover injection timing relative to meals and sleep, optimal pre-bed dosing strategies, and subjective reports of improved sleep architecture and morning recovery. See active threads at r/Peptides and r/PeptidesResearch.
Potential Benefits Studied
- Visceral fat reduction: Tesamorelin is the only GHRH analogue with FDA-approved evidence for clinically meaningful VAT reduction.
- Lean mass support: GH-mediated IGF-1 elevation promotes nitrogen retention and may support preservation of skeletal muscle, particularly in catabolic states.
- Metabolic improvements: Research shows favorable changes in lipid profiles (triglycerides, HDL) and glucose metabolism markers with sustained use.
- Cognitive function: Emerging evidence links GH/IGF-1 axis stimulation to improved executive function and verbal memory in older adults.
- Bone mineral density: Preclinical and early clinical data suggest GH secretagogues may attenuate age-related bone loss.
- Sleep quality: GH is predominantly secreted during slow-wave sleep; GH secretagogues administered pre-sleep may deepen slow-wave sleep architecture.
- Skin and connective tissue: IGF-1-mediated collagen synthesis is a frequently reported subjective endpoint in research communities.
Dosage & Administration
Both tesamorelin and ipamorelin are peptides requiring subcutaneous injection following reconstitution with bacteriostatic water. In the human clinical literature, tesamorelin is studied most at 1–2 mg/day subcutaneously. Ipamorelin is typically researched at 100–300 mcg per injection. The 5mg/5mg combination vial provides a convenient equimolar starting point for researchers exploring the synergistic GHRH+GHRP protocol.
Injections are ideally administered in a fasted state—either upon waking or 2+ hours after the last meal—to avoid blunting the GH pulse with elevated insulin. Pre-sleep administration is another widely studied timing strategy, as it aligns with the body’s natural nocturnal GH surge. Researchers frequently report the best outcomes with 1–2 injections per day on a 5-days-on/2-days-off protocol to prevent receptor desensitization.
Storage: Lyophilized peptides should be kept refrigerated (2–8°C) and protected from light. Reconstituted solutions should be used within 30 days when stored at 4°C.
Where to Find It
Researchers looking to source the Tesamorelin/Ipamorelin 5mg/5mg combination for laboratory use can find it at combatresearch.is. Combat Research maintains rigorous quality standards for all research compounds.
Conclusion
The tesamorelin/ipamorelin combination represents one of the most scientifically supported GH-axis peptide stacks available in 2026. Tesamorelin’s robust clinical evidence base—including an FDA approval—combined with ipamorelin’s clean receptor selectivity and minimal cortisol/prolactin activity creates a mechanistically elegant and well-tolerated research framework. With growing evidence connecting GH/IGF-1 signaling to metabolic health, cognitive aging, and body composition, this combination remains at the forefront of serious peptide research.
Disclaimer: This article is intended for educational and research purposes only. Tesamorelin and ipamorelin are research compounds and are not approved for human self-administration outside of clinical settings. This content does not constitute medical advice. Always consult a qualified healthcare professional before considering any peptide protocol. Combat Research sells these compounds exclusively for legitimate research purposes.
